Bourdin A, Mifsud NA, Chanez B, Chanez P, Snell G, Kotsimbos TC. Clara cells and injury post lung transplantation: an evolving story. Am J Transplant 2013 Mar 6. doi: 10.1111/ajt.12184. [Epub ahead of print].
Brew BJ, Gray L, Lewin S, Churchill M (2013). Is specific HIV eradication from the brain possible or needed? Expert Opinion on Biological Therapy 2013 Accepted
Lee H, Hamilton JR. The PAR1 antagonist, SCH79797, alters platelet morphology and function independently of PARs. Thromb Haemost. 2013 Jan 8;109(1):164-7.
Prickett SR, Voskamp AL,Phan T, Dacumos-Hill A, Mannering SI, Rolland JM, and O’Hehir RE. Ara h 1 CD4+ T-cell epitope-based peptides: candidates for a peanut allergy therapeutic. Clinical and Experimental Allergy. Accepted for publication March 2013.
Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X and Marcelli C. Anti-drug antibodies (ADAb) to tumour necrosis factor (TNF) - specific neutralizing agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2012.
Vincent FB, Bourke P, Morand EF, Mackay F and Bossingham D. Focus on systemic lupus erythematosus in Indigenous Australians: toward a better understanding of autoimmune diseases. Intern Med J 2012 Nov 23.
Wilkins, Simon, et al. "Insertion/Deletion Polymorphisms in the ΔNp63 Promoter Are a Risk Factor for Bladder Exstrophy Epispadias Complex." PLoS Genetics 8.12 (2012): e1003070.